Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial Ma et al. eClinicalMedicine

https://www.thelancet.com/series/lung-cancer-asia?dgcid=hubspot_email_infocusalerts-oncology_feature_lungcancerasia24&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-95FFCwZW7S-dTrfspZ85ASrIwWdkukCypXAU0In5uUPTD0vqDWSDiNrAdy3tqQBzixQb1MlpFlGsPzBENOvONU_Ldzeg&_hsmi=319552803&utm_content=319101856&utm_source=hs_email